

# **LANDMARK Trial: A prospective, multinational, multicentre, open-label, randomised, noninferiority trial to compare safety and effectiveness of Meril\*s Myval Transcatheter Heart Valve (THV) series vs. Contemporary Valves (Edwards\* Sapien THV series and Medtronic\*s Evolut THV series) in patients with severe symptomatic native aortic valve stenosis.**

Published: 09-07-2020

Last updated: 07-06-2025

LANDMARK Trial is designed to compare safety and effectiveness of Meril\*s Myval Transcatheter Heart Valve (THV) series vs. Contemporary Valves (Edwards\* Sapien THV series and Medtronic\*s Evolut THV series) in patients with severe symptomatic native...

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Recruitment stopped
<b>Health condition type</b>	Cardiac valve disorders
<b>Study type</b>	Interventional

## **Summary**

### **ID**

NL-OMON56440

### **Source**

ToetsingOnline

### **Brief title**

Landmark

## Condition

- Cardiac valve disorders

### Synonym

Severe aortic stenosis

### Research involving

Human

## Sponsors and support

**Primary sponsor:** Meril Life Sciences Pvt. Ltd.

**Source(s) of monetary or material Support:** Industrie

## Intervention

**Keyword:** Severic aortic valve stenosis, TAVR

## Outcome measures

### Primary outcome

Primary study parameters/outcome of the study:

It is the composite of following (at 30 days) VARC-3 defined criteria:

- All-cause mortality
- All stroke
- Bleeding (Type 3 and 4)
- Acute kidney injury (stage 2, 3 and 4)
- Major vascular complications
- Moderate or severe prosthetic valve regurgitation
- Conduction system disturbances resulting in a new permanent pacemaker implantation

### Secondary outcome

2 - LANDMARK Trial: A prospective, multinational, multicentre, open-label, randomise ... 14-06-2025

1- It is the composite of following [at 1-year] (VARC-3 defined criteria):

- All-cause mortality
- All stroke
- Bleeding (Type 3 and 4)
- Acute kidney injury (stage 2, 3 and 4)
- Major vascular complications
- Moderate or severe prosthetic valve regurgitation
- Conduction system disturbances resulting in a new permanent pacemaker implantation

2- All-cause mortality (VARC-3 defined criteria) (till 10-year)

3- All stroke (VARC-3 defined criteria till 5-year)

4. Acute Kidney Injury (AKI)( stage 2, 3 and 4) (VARC-3 defined criteria) (till 1-year)

5. Bleeding (Type 3 and 4) (VARC-3 defined criteria) (till 5-year)

6. Moderate or severe prosthetic valve regurgitation (VARC-3 defined criteria) (10-year)

7. New permanent pacemaker implantation (VARC-3 defined criteria) (till 10-year)

8. Conduction disturbances and arrhythmias (VARC-3 defined criteria(till 5-year)

9. Technical success (VARC-3 defined criteria) [Time Frame: Post-procedure]

10 Device success (VARC-3 criteria)

11 Safety at 30 days (VARC-3 criteria)

12 Clinical efficacy at 30 days (VARC-2 criteria)

13. Valve related long-term clinical efficacy (VARC-3 defined criteria) (till 10 years)

14. Vascular and access related complications (VARC-3 defined criteria) (till 1-year)

15. Major vascular complications (VARC-3 defined criteria) (till 1-year)

16. Myocardial Infarction (VARC-3 defined criteria) (till 5-year)

17. Functional improvement from baseline as measured per

- NYHA class

- 6 minute walking test

- 18 - Echocardiographic parameters (till 10 years)
- 19- Bioprosthetic valve deterioration (VARC-3 defined criteria (5-year)
20. Patient-prosthesis mismatch (VARC-2 defined criteria) (till 1-year)
- 21 Days Length of index hospital stay
- 22 Re-hospitalization (VARC-3 defined criteria) (5-year)
23. Health status as evaluated by Quality of Life questionnaires
24. Valve thrombosis (VARC-2 defined criteria) (till 5-year)
25. Coronary obstruction requiring intervention (VARC-3 defined criteria)
26. Valve malpositioning (VARC-3 defined criteria
27. Conversion to open surgery (VARC-3 defined criteria)
28. Unplanned use of mechanical circulatory support (cardiopulmonary bypass (CPB), extracorporeal membrane oxygenation (ECMO), transcatheter pumps or intra-aortic balloon pump (IABP) (VARC-3 defined criteria)

29. Implantation of multiple (>1) transcatheter valves during the index hospitalization (VARC-3 defined criteria)

30. Cardiac structural complications (VARC-3 defined criteria) (till 5 years)

31. Ventricular septal perforation (VARC-2 defined criteria)

32. New onset of atrial fibrillation or atrial flutter (VARC-3 defined criteria) (till 5-year)

33. Endocarditis (VARC-3 defined criteria) (till 5-year]

## Study description

### Background summary

Aortic stenosis (AS) is one of the most prevalent diseases in the elderly patient population (>65 years of age). The estimated prevalence of the disease varies from 2% to 7% in the elderly population. The disease has a significant impact on patient morbidity and mortality as well as healthcare expenditures. Transcatheter aortic valve implantation (TAVI) has been introduced to treat patients with severe symptomatic aortic stenosis

### Study objective

LANDMARK Trial is designed to compare safety and effectiveness of Meril's Myval Transcatheter Heart Valve (THV) series vs. Contemporary Valves (Edwards' Sapien THV series and Medtronic's Evolut THV series) in patients with severe symptomatic native aortic valve stenosis

### Study design

This is a prospective, randomised, multinational, multicentric, open-label non-inferiority trial to compare clinical outcomes of Myval THV Series vs.

Contemporary Valves in severe symptomatic native aortic valve stenosis patients via transfemoral approach. The trial includes a total of 768 subjects across the globe.

A non-randomised nested registry will be conducted to include patients requiring extra-large size (30.5 mm and 32 mm) of Myval THV (XL Nested Registry)

## **Intervention**

1 group (384 patients) will be treated with the Myval transcatheter heartvalve.

1 group (384 patients) will be treated with the Edwards Sapien or Medtronic Evolut heartvalve.

For the nested registry approximately 100 patients will be recruited from approximately 30 participating centres in the LANDMARK trial.

## **Study burden and risks**

Based on current experience we do not expect extra risks.

## **Contacts**

### **Public**

Meril Life Sciences Pvt. Ltd.

Bilakhia House, Survey 135/139

Chala Vapi Muktanand Marg

IN

### **Scientific**

Meril Life Sciences Pvt. Ltd.

Bilakhia House, Survey 135/139

Chala Vapi Muktanand Marg

IN

## **Trial sites**

### **Listed location countries**

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

As per local Heart Team assessment, patient is eligible for TAVI and the patient is suitable for implantation with all three study devices.

### Exclusion criteria

Any condition, which in the Investigator\*s opinion, would preclude safe participation of patient in the study.

## Study design

### Design

Study phase:	4
Study type:	Interventional
Intervention model:	Other
Allocation:	Randomized controlled trial
Masking:	Open (masking not used)
Control:	Active
Primary purpose:	Treatment

### Recruitment

NL	
Recruitment status:	Recruitment stopped
Start date (anticipated):	26-11-2020
Enrollment:	422
Type:	Actual



## Medical products/devices used

Generic name: Transcatheter heart valve  
Registration: Yes - CE intended use

## Ethics review

Approved WMO  
Date: 14-10-2020  
Application type: First submission  
Review commission: MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO  
Date: 22-12-2020  
Application type: Amendment  
Review commission: MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO  
Date: 26-03-2021  
Application type: Amendment  
Review commission: MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO  
Date: 05-08-2021  
Application type: Amendment  
Review commission: MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO  
Date: 12-10-2021  
Application type: Amendment  
Review commission: MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO  
Date: 21-12-2021  
Application type: Amendment  
Review commission: MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Approved WMO

Date:	16-02-2022
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO	
Date:	01-06-2022
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO	
Date:	19-07-2023
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO	
Date:	23-11-2023
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO	
Date:	11-06-2024
Application type:	Amendment
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

**In other registers**

Register	ID
Other	NCT0427526 ClinicalTrial.gov
CCMO	NL73302.100.20